PARP Inhibitors Synergize with Gemcitabine by Potentiating DNA Damage in Non-Small Cell Lung Cancer

Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated great promise in the treatment of patients with deficiencies in homologous recombination (HR) DNA repair, such as those with loss of BRCA1 or BRCA2 function. However, emerging studies suggest that PARP inhibition can also target HR-com...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Cancer
Hlavní autoři: Jiang, Yu, Dai, Hui, Li, Yang, Yin, Jun, Guo, Shuliang, Lin, Shiaw-Yih, McGrail, Daniel J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6320711/
https://ncbi.nlm.nih.gov/pubmed/30152517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.31770
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky